Kaleido Biosciences, Inc.
KLDO · OTC
12/31/2021 | 9/30/2021 | 6/30/2021 | 3/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.30 | 0.97 | -0.30 |
| FCF Yield | -17.59% | -7.01% | -6.42% | -7.47% |
| EV / EBITDA | -4.39 | -9.11 | -11.76 | -11.51 |
| Quality | ||||
| ROIC | -56.07% | -39.76% | -31.56% | -23.76% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.85 | 0.69 | 0.84 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,033,429.85% | 949,022.00% | 1,072,211.65% | 1,083,400.30% |
| Free Cash Flow Growth | -7.90% | 19.72% | 15.37% | -100.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.89 | 1.57 | 2.24 | 3.27 |
| Interest Coverage | -27.55 | -31.61 | -32.92 | -31.52 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |